Target intelligence / Profile preview

FAM111A divergent transcript (FAM111A-DT)

Target
FAM111A-DT
Molecular classification
Long noncoding RNA
01

Overview

FAM111A divergent transcript (FAM111A-DT) is a long noncoding RNA (lncRNA) transcribed from the genomic region near the FAM111A gene. Unlike the protein-coding FAM111A, FAM111A-DT does not encode a protein. Instead, it functions in the regulation of gene expression. Recent research has indicated that FAM111A-DT is upregulated in hepatocellular carcinoma (HCC), where it facilitates cancer cell proliferation, DNA replication, and tumor growth. These functions are mediated through N^6-methyladenosine (m^6A) modification, which enables FAM111A-DT to bind the m^6A reader YTHDC1 and recruit the histone demethylase KDM3B, thereby activating the FAM111A promoter and increasing FAM111A expression. FAM111A-DT has been suggested as a negative prognostic marker in HCC and is a candidate for future therapeutic targeting, although it currently has no approved drugs targeting it directly.

Other names
FAM111A-DTFAM111ADTFAM111A divergent transcript lncRNA
02

Mechanism of action

Acts as a regulatory lncRNA that modulates transcription of the FAM111A gene by recruiting epigenetic modifiers (such as KDM3B and YTHDC1) through m^6A methylation

03

Biological functions

Gene expression regulationPromotion of cellular proliferationRegulation of DNA replicationEpigenetic modification (via m^6A methylation)
04

Disease associations

Cancer (notably hepatocellular carcinoma)Potential involvement in tumor progression
05

Safety considerations

None specifically reported; the main safety issue would relate to its potential as a cancer biomarker or target for new therapies, but these are investigational
06

Biomarkers

FAM111A-DT expression and its m^6A methylation state have been proposed as markers for poor prognosis in hepatocellular carcinoma

Beyond the preview

Go deeper on FAM111A divergent transcript (FAM111A-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAM111A divergent transcript (FAM111A-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call